Pharmacokinetics of 99tcm-pertechnetate and 188re-perrhenate after oral administration of perchlorate option for subsequent care after the use of liquid 188re in a balloon catheter

Nuclear Medicine Communications

Volumn 19, Issue 8, 1998, Pages 795-802

  Kotzerke, J ^a   Fenchel, S ^a   Guhlmann, A ^a   Rentschler, M ^a   Reske, S N ^a   Stabin, M ^b   Knapp, F F ^c  

^a UNIVERSITY OF ULM   (Germany)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERCHLORIC ACID; PERRHENIC ACID; PERTECHNETIC ACID TC 99M; RADIOISOTOPE; RHENIUM; SODIUM DERIVATIVE; SODIUM PERCHLORATE; RHENIUM 188;

ADULT; AGED; ARTICLE; BALLOON DILATATION; BRACHYTHERAPY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RADIATION EXPOSURE; RECURRENT DISEASE; SCINTISCANNING; THYROID GLAND; TRANSLUMINAL CORONARY ANGIOPLASTY; CLINICAL ARTICLE; CORONARY ARTERY OBSTRUCTION; DRUG UPTAKE; FOLLOW UP; RESTENOSIS; RISK ASSESSMENT; THYROID SCINTISCANNING; WHOLE BODY SCINTISCANNING;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BALLOON DILATATION; BRACHYTHERAPY; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCHLORIC ACID; RADIOISOTOPES; RECURRENCE; RHENIUM; SODIUM COMPOUNDS; SODIUM PERTECHNETATE TC 99M; THYROID GLAND;

EID: 0031596037     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-199808000-00011     Document Type: Article

References (21)

1. Califf RM, Fortin DF, Fnd DJ et al. Restenosis after coronary angioplasty: An overview. J Am Coll Cardiol 1991; 17; 2B-13B.
2. Leimgruber PP, Roubin GS, Hollman J et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986; 73; 710-717.
3. Hanke H, Strohschneider T, Oberhoff M Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res 1990; 67; 651-659.
4. Teirstein PS, Massullo V, Jani S et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336; 1697-1703.
5. Popowski Y, Verin V, Papirov I et al. Intra-arterial 90Y bra-chytherapy; Preliminary dosimetric study using a specially modified angioplasty balloon, Int J Radiat Oncol Biol Phys 1995; 33; 713-717.
6. Amols HI, Reinstein LE, Weinberger J. Dosimetry of a radioactive coronary balloon dilitation catheter for treatment of neointimal hyperplasia. Med Phys 1996; 23: 1783-1788.
7. Amols HI, Zaider M, Weinberger J et al. Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries. Int J Radiat Oncol Biol Phys 1996; 36: 913-921.
8. Knapp FF Jr, Beets AL, Guhlke S et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res 1997; 17: 1783-1795.
9. Deutsch E, Libson K, Vanderheyden JL et al. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl lustrum B 1986; 13: 465-477.
10. Oldendorf WH, Sisson WB, Lisaka Y. Compartmental redistribution of 99mTc-pertechnetate in the presence of perchlorate ion and its relation to plasma protein binding. I Nucl Med 1970; 11: 85-88.
11. Prince JR, Bancroft S, Dukstein WG. Pharmacokinetics of pertechnetate administered after pretreatment with 400 mg of potassium perchlorate: Concise communication. J Nucl Med 1980; 21: 763-766.
12. Reinecke V, Piaszek L, Strotges MW Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration. Nuklcnniiediziu 1975; 13: 360-370.
13. Becker D, Charkes ND, Dworkin H Procedure guideline for thyroid uptake measurement: 1.0. Society of Nuclear Medicine. J Nucl Med 1982; 37: 1266-1268.
14. Lathrop KA, Atkins HL, Berman M Report No. 8: Technetium-99m as sodium pertechnetate. In: Loevinger R, Budinger TF, Watson EE, eds. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, 1988: 65-69.
15. Stabin, M. MIRDOSE-the personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med 199b; 37: 538-546.
16. Golstein P, Abramow M, Dumont JE The iodide channel of the thyroid: A plasma membrane vesicle study. Am J PIii/biol 1992; 263: C590-C597.
17. Hilditch TE, Birnie GG, Sik MI Use of perchlorate to block gastric uptake of free 99Tcm in the investigation of gastrointestinal bleeding. Nucl Med Commun 1985; 6: 701-706.
18. Bardfeld PA, Shulman K. Transport and distribution of rhenium-188 in the central nervous system. Exp Neurol 1976; 50: 1-13.
19. Snnpkin DJ, Mackie TR. EGS4 Monte Carlo determination of the beta dose kernel in water. Med Pln/s 1990; 17: 179-186.
20. Stabin MG, Evans JF. Radiation dose to the wall of blood vessels containing various radionuclides. J Nucl Med 1996; 37: 229P.
21. Kotzerke J, Rentschler M, Glattmg G Dosimetric fundamentals of endovascular brachytherapv using Re-188 to prevent restenosis after angioplasty Nuklcnniiediziu 1998; 37: 68-72.